Please assess the completion status of the following clinical trial:

Trial Title: BAX 855 Dose-Escalation Safety Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is male and is 18 to 65 years of age at the time of screening~* The subject has severe hemophilia A (factor VIII level \< 1%)~* The subject was previously treated with plasma-derived factor VIII (FVIII) concentrates or recombinant FVIII for at least 150 exposure days (EDs)~Exclusion Criteria:~* The subject has a detectable FVIII inhibitor at screening, with a titer \>= 0.6 BU~* The subject has a documented history of FVIII inhibitors with a titer \>= 0.4 BU at any time prior to screening~* The subject has a known hypersensitivity towards mouse or hamster proteins or to polyethylene glycol (PEG)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Low dose of ADVATE followed by low dose of BAX 855
- Cohort 2 (Type: EXPERIMENTAL): High dose of ADVATE followed by high dose of BAX 855

Based on this trial design, predict the completion outcome and termination type (if applicable).